Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;43(6):744-5.
doi: 10.4103/0253-7613.89847.

Tolerance of bladder antispasmodics in children with urinary incontinence: An observational study from North India

Vishal Bansal  1 , Bikash Medhi, Om Prakash, Balbinder Kaur, Kl Narasimhan
Affiliations

Tolerance of bladder antispasmodics in children with urinary incontinence: An observational study from North India

Vishal Bansal et al. Indian J Pharmacol. 2011 Nov.
No abstract available

PubMed Disclaimer

References

    1. [Last accessed on 2010 Dec 12]. Available from: http://www.fda.gov/fdac/features/2005/505_incontinence.html#meds .
    1. Siddique MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64:885–912. - PubMed
    1. Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, Lee KS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol. 2002;9:247–52. - PubMed
    1. Yucel S, Akkaya E, Guntekin E, Kukul E, Danisman A, Akman S, et al. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Urology. 2005;65:369–73. - PubMed
    1. Bolduc S, Upadhyay J, Payton J, Bägli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure. BJU Int. 2003;91:398–401. - PubMed